2026 Global: Digital Dose Inhaler Market-Competitive Review (2032) report
Description
The 2026 Global: Digital Dose Inhaler Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
ResMed, headquartered in San Diego, United States, through its Propeller Health collaboration, is a leading force in the digital dose inhaler market, delivering sensor-enabled inhalers, cloud analytics, and clinician dashboards that monitor usage, adherence, and outcomes for asthma and COPD. The company integrates inhaler devices with mobile and web platforms, enabling real-time feedback, remote monitoring, and population health management across payers and providers. GlaxoSmithKline (GSK) contributes a comprehensive SmartInhaler portfolio that captures dose events and transmits data to connected health ecosystems, supporting personalized treatment and adherence interventions; GSK is headquartered in London, United Kingdom, anchoring its research, development, and commercial operations. Adherium, a New Zealand-based developer of the Hailie digital inhaler ecosystem, delivers sensor-enabled devices, data analytics, and patient engagement tools designed to improve inhaler technique and use; its headquarters are in Auckland, New Zealand. Philips, offers inhaler sensors as part of respiratory care solutions, with headquarters in Amsterdam, Netherlands.
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, participates in the digital inhaler ecosystem through collaborations that enhance dose-logging, telemetry, and patient support across respiratory indications. The company leverages established inhaler platforms with sensor-enabled accessories to provide real-time adherence insights and remote coaching within integrated care programs. Teva Pharmaceutical Industries, based in Petah Tikva, Israel, integrates connected inhaler technologies with its broad portfolio of generic and branded inhalers, enabling dose-tracking and data sharing with care teams. 3M, headquartered in Saint Paul, United States, contributes sensing capabilities and materials that can be embedded in inhaler devices or accessories, expanding opportunities for analytics in clinical deployments. AstraZeneca, based in Cambridge, United Kingdom, pursues partnerships that couple proprietary inhaled therapies with digital health platforms to optimize adherence and dosing history across multi-country trials. These efforts emphasize data interoperability, privacy, and outcomes-based approaches that inform clinicians and payers. The market continues to consolidate rapidly.
Novartis, headquartered in Basel, Switzerland, has advanced through partnerships that couple its inhaled therapies with digital health platforms to enable dose logging, adherence benchmarking, and remote patient monitoring in COPD and asthma programs. The company's involvement in sensor-integrated inhalers complements its portfolio of medicines, with collaborations aimed at standardizing data streams, supporting adherence initiatives, and informing clinical decision-making. Sanofi, based in Paris, France, has engaged with digital inhaler developers to embed connectivity into its inhalation devices and to enable data sharing across care teams. These efforts align with broader industry shifts toward value-based respiratory care, incentivizing adherence, optimizing dosing, and improving patient outcomes through real-time feedback and population health analytics. Together, Novartis and Sanofi contribute to a more integrated, data-driven inhaler ecosystem that supports clinicians while empowering patients to manage their conditions more effectively. Continued collaboration among manufacturers, technology partners, and regulators will shape evidence-based practice across healthcare systems globally.
ResMed, headquartered in San Diego, United States, through its Propeller Health collaboration, is a leading force in the digital dose inhaler market, delivering sensor-enabled inhalers, cloud analytics, and clinician dashboards that monitor usage, adherence, and outcomes for asthma and COPD. The company integrates inhaler devices with mobile and web platforms, enabling real-time feedback, remote monitoring, and population health management across payers and providers. GlaxoSmithKline (GSK) contributes a comprehensive SmartInhaler portfolio that captures dose events and transmits data to connected health ecosystems, supporting personalized treatment and adherence interventions; GSK is headquartered in London, United Kingdom, anchoring its research, development, and commercial operations. Adherium, a New Zealand-based developer of the Hailie digital inhaler ecosystem, delivers sensor-enabled devices, data analytics, and patient engagement tools designed to improve inhaler technique and use; its headquarters are in Auckland, New Zealand. Philips, offers inhaler sensors as part of respiratory care solutions, with headquarters in Amsterdam, Netherlands.
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, participates in the digital inhaler ecosystem through collaborations that enhance dose-logging, telemetry, and patient support across respiratory indications. The company leverages established inhaler platforms with sensor-enabled accessories to provide real-time adherence insights and remote coaching within integrated care programs. Teva Pharmaceutical Industries, based in Petah Tikva, Israel, integrates connected inhaler technologies with its broad portfolio of generic and branded inhalers, enabling dose-tracking and data sharing with care teams. 3M, headquartered in Saint Paul, United States, contributes sensing capabilities and materials that can be embedded in inhaler devices or accessories, expanding opportunities for analytics in clinical deployments. AstraZeneca, based in Cambridge, United Kingdom, pursues partnerships that couple proprietary inhaled therapies with digital health platforms to optimize adherence and dosing history across multi-country trials. These efforts emphasize data interoperability, privacy, and outcomes-based approaches that inform clinicians and payers. The market continues to consolidate rapidly.
Novartis, headquartered in Basel, Switzerland, has advanced through partnerships that couple its inhaled therapies with digital health platforms to enable dose logging, adherence benchmarking, and remote patient monitoring in COPD and asthma programs. The company's involvement in sensor-integrated inhalers complements its portfolio of medicines, with collaborations aimed at standardizing data streams, supporting adherence initiatives, and informing clinical decision-making. Sanofi, based in Paris, France, has engaged with digital inhaler developers to embed connectivity into its inhalation devices and to enable data sharing across care teams. These efforts align with broader industry shifts toward value-based respiratory care, incentivizing adherence, optimizing dosing, and improving patient outcomes through real-time feedback and population health analytics. Together, Novartis and Sanofi contribute to a more integrated, data-driven inhaler ecosystem that supports clinicians while empowering patients to manage their conditions more effectively. Continued collaboration among manufacturers, technology partners, and regulators will shape evidence-based practice across healthcare systems globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
